Contraception 2000: Lunelle(TM), an injectable combination contraceptive option

L. P. Shulman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Contraceptive choices for women in the United States will soon expand with the expected Food and Drug Administration (FDA) approval (in early summer 2000) of a once-a-month injectable combination contraceptive. Containing 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate (MPA/E2C) (Lunelle(TM)/Lunella(TM), Pharmacia and Upjohn, Peapack, NJ), this monthly injectable method combines the convenience and contraceptive efficacy of long-acting steroid methods with the cycle control, return to fertility, and side effect profile more typical of combination low-dose oral contraceptives. The introduction of this novel contraceptive will expand the number of safe, convenient, and effective contraceptives, and it may be used and accepted by women who are not or have not been inclined to use an available reversible contraceptive method in a correct and consistent manner.

Original languageEnglish (US)
Pages (from-to)725-729
Number of pages5
JournalJournal of Women's Health and Gender-Based Medicine
Issue number7
StatePublished - Oct 18 2000

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Contraception 2000: Lunelle(TM), an injectable combination contraceptive option'. Together they form a unique fingerprint.

Cite this